Form 4: Acadia Pharmaceuticals Officer James Kihara Reports Stock Sales

James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, reports the sale of 4,000 shares of common stock on May 16, 2025, under a pre-arranged trading plan.

Summary

• James Kihara, the Principal Accounting Officer of Acadia Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On May 16, 2025, Kihara sold 2,000 shares of common stock at $25 per share and another 2,000 shares at $20 per share.
• These sales were executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.
• Following these transactions, Kihara directly owns 20,395 shares of Acadia Pharmaceuticals.
• This includes 869 shares acquired on May 15, 2025, through an employee stock purchase plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged trading plan, with a small acquisition through an employee stock purchase plan. There's no inherent positive or negative signal.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The stock sales by a company officer could be perceived negatively by some shareholders, potentially leading to slight downward pressure on the stock price in the short term.
• However, the existence of a pre-arranged trading plan mitigates this concern.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Sale, Acadia Pharmaceuticals, Kihara, ACAD, Rule 10b5-1